JOBS Act Summary: The Reed Smith Bulletin
Reed Smith LLP, a global business law firm, recently issued a JOBS Act bulletin to its network. The bulletin, co-authored by seven partners on both coasts, summarizes and analyzes the JOBS Act.
News
Patent Infringement Special Report: Part III, the Future of Drug Development
Part Three of our Special Report analyzes what may be one of the first ‘test cases’ of the new patent infringement precedent.
Patent Infringement Special Report: Part II, History and Precedent
Part two of our Special Report highlight an important case that may significantly affect the patent infringement landscape. Shares of Myriad Genetics fell 10 percent in the wake of the Mayo ruling.
PLC Announces Approval to Distribute RenalGuard® in Brazil
“Approval to sell RenalGuard in Brazil is yet another significant development for PLC,” said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems.
ALS TDI -The First Non Profit Biotech, A Hidden Investment Opportunity?
Strategically, the organization has done a good job in moving drugs through clinical trials but lacks venture capital funding. But the benefit investors stand to gain is a major stakehold in the drug with a low investment.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Patent Infringement Special Report: Part I, The Most Pressing Case
OneMedPlace is publishing a special in-depth look into the state of patent infringement in drug manufacturing.
OncoSec Closes $7.75 Million Public Offering
OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.
The 4 Small Diabetes Diagnostics Companies You Overlooked
Some experts believe large pharmaceutical companies have reached a plateau in market growth. However, that doesn’t tell the whole story, as new companies with disruptive technology have made some significant advancements in 2012.